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Abstract: Here we describe a female patient who developed acute promyelocytic leukemia (APL) characterized by t(l5;17)   translocation 
at diagnosis. The patient began treatment with all-trans retinoic acid (ATRA) + chemotherapy. During follow up, the patient was found 
to be negative for the t(15;17) transcript after 3 months of therapy which remained undetectable, thereafter. However, the emergence 
of a small clone with a t(8;21) abnormality was observed in the bone marrow and peripheral blood (PB) cells between 3 and 18 months 
  following treatment initiation. The abnormal translocation observed in PB cells obtained at 3 months was detected after the second 
cycle of consolidation therapy and reappeared at 15 months during maintenance treatment, a period without ATRA. Although based 
on a   single case, we conclude that genetic screening of multiple translocations in AML patients should be requested to allow early 
­ identification­of­other­emerging­clones­during­therapy­that­may­manifest­clinically­following­treatment.
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Introduction
Acute myeloid leukemia (AML) is the most common 
form  of  adult  leukemia,  and  account  for  approxi-
mately  10,000  newly  diagnosed  cases  per  year.1 
Previous­studies­have­identified­a­group­of­chromo-
somal translocations in myeloid cells that create an 
oncogenic  fusion  gene  that  is  associated  with  the 
various subtypes of AML (M1 through M6) accord-
ing  to  the  current  French-American-British  (FAB) 
classification­ system.­ These­ chromosomal­ translo-
cations underlie the phenotypic variability observed 
in AML subtypes.2­The­WHO­classification­divides­
AML into the following 4 major categories; 1) AML 
with recurring genetic abnormalities; 2) AML with 
multilineage dysplasia; 3) therapy-related and myel-
odysplastic syndromes AML; and 4) AML not oth-
erwise­specified.­The­first­category­consists­of­the­
following  subcategories:  a) AML  t(8;21)(q22;q22), 
(RUNX1/RUNXT1);  b)  AML  with  abnormal  bone 
marrow eosinophils and inv(16)(p13q22) or t(16;16)
(p13;q22), (CBFb/MYH11); and c) acute promyelo-
cytic leukemia (APL) with t(15;17)(q22;q12), (PML/
RARA) and variants; and d) AML with 11q23/MLL 
abnormalities. The 3 most common reciprocal trans-
locations  include  the  chimeric  genes  PML/RARA 
resulting­ from­ t(15;17),­ which­ specifically­ char-
acterizes 100% of FAB M3 AML cases; the fusion 
transcript  RUNX1/RUNXT1  resulting  from  t(8;21) 
detected in 20% of FAB M2 AML cases, and CBFb/
MYH11 resulting from inv(16)/t(16;16) found in at 
least 70% of M4 AML with eosinophilia.3–7 Advances 
in understanding cytogenetic and molecular pathogen-
esis of AML have allowed researchers to design more 
sophisticated therapeutic protocols. For example, the 
advent of all-trans-retinoic acid (ATRA) therapy in 
conjunction with cytotoxic agents, such as cytarabine 
or idarubicin, increases the killing of clonogenic cells 
and­significantly­improve­AML­prognosis.8–14 Several 
AML studies have evaluated the prognostic impact 
of these translocations and found that rearrangement 
t(15:17), which characterizes the APL form of acute 
myeloid  leukemia,  as  well  as  t(8;21)  and  inv(16)/
t(16;16), is associated with a favorable outcome com-
pared to other AML rearrangements. Thus, molecular 
identification­of­these­rearrangements­is­of­clinical­
importance.
Although treatment with ATRA alone is neither 
able to eradicate the leukemic clone nor completely 
cure  APL,  it  can  induce  complete  morphological 
remission in 80%–90% of APL patients and reduce the 
mortality rate from 85% to less than 10%.15 Despite 
the  impressive  complete  remission  rates  obtained 
with ATRA as a single agent, a shortcoming of this 
therapy is the risk of overproduction of white cells 
and the rapid development of drug resistance.
The  emergence  of  clonal  chromosome  changes 
unrelated to the initial abnormal APL clone during 
combined therapy is a rare event, and only a few cases 
have been reported in the literature. Here, we pres-
ent a female APL patient positive for t(15:17) who 
achieved complete remission through the disappear-
ance of the t(15;17) PML-RARA transcript following 
ATRA treatment in combination with chemotherapy. 
However, a novel t(8;21) rearrangement was detected 
in this patient’s PB cells after initiation of consolida-
tion therapy. Diagnosis of APL–AML in this patient 
was based on karyotyping, immunophenotyping, and 
molecular studies of both PB and bone marrow cells.
case Report
In  April  2008,  a  21-year-old  female  was  admit-
ted to our institute with a 15 day history of spon-
taneous bruising of the extremities and one day of 
hypermenorrhea. General physical examination was 
unremarkable except for slightly pale yellow skin. 
An evaluation of isolated PB cells allowed for the 
assessment of hemoglobin levels (9.0 g/dL) and a, 
WBC count (22.7 × 109/L with 82% blast cells, 0% 
promyelocytes,  5.7%  neutrophils,  10.1%  lympho-
cytes). Besides elevated lactate dehydrogenase levels 
(760 IU/L), all biochemical parameters were within 
normal limits. In the coagulation screening test, the 
thrombin  time  (TT),  prothrombin  time  (PT),  and 
international normalized ratio (INR) were prolonged 
(TT: 27.7 sec—range 16 to 22; PT: 47%, INR: 1.6) 
although the activated partial thromboplastin time was 
within normal limits. The patient had a platelet count 
of 28 × 109/L and, as a result, was transfused with 
1unit of apheresis platelets and 6 units of fresh-frozen 
plasma resulting in an increase in platelets. A bone 
marrow sample collected at the time of admission was 
markedly hypercellular with 62.8% blasts and 31.6% 
atypical promyelocytes. Cytochemical staining dem-
onstrated that all blast cells were intensely positive 
for myeloperoxidase and Sudan Black B, but nega-
tive­for­nonspecific­esterase.­Immunophenotyping­of­early detection of t(8;21) transcript during treatment of a patient with ApL
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bone­marrow­blast­cells­by­flow­cytometry­revealed­
the­following­myeloid­markers­on­infiltrating­cells:­
CD45+, CD34+/−, HLA-DR+, CD13++, CD33++, CD64+/− 
with partial co-expression of the T cell–  associated 
antigen CD2 and CD56 negative.
chromosomal Analysis
Chromosomal studies were performed on short term 
unstimulated  cultures  of  bone  marrow  cells  using 
the G banding conventional technique. The karyo-
type was performed as described according to ISCN 
2005.16 At least 24 metaphase cells were fully karyo-
typed  and  interpreted  as  46,XX,t(15;17)(q22;q21)
[8]/46,XX[16]17 (Fig. 1).
Molecular studies
Bone marrow and PB samples were collected at the 
time of diagnosis, after remission induction, at the end 
of  consolidation,  and  throughout  the  maintenance 
therapy.  Total  RNA  from  mononuclear  cells  was 
extracted with TRIzol (Invitrogen). The reverse tran-
scription reaction was performed on 1 µg of total RNA 
using Superscript III, random hexamers and oligo(dT) 
primers (Invitrogen). As is routine, multiplex real-
time PCR was performed at the time of diagnosis to 
simultaneously detect PML/RARA t(15:17), RUNX1/
RUNXT1  t(8;21),  and  the  CBFb/MYH11  inv(16)/
t(16;16) fusion gene transcripts. The   following three 
previously published primer pairs were added to the 
reaction  mixture:  PML-C2/RARA-D  for  the  PML/
RARA t(15;17) fusion transcripts, AML1-C/ETO-D for 
the RUNX1/RUNXT1 t(8:21) fusion transcripts, and 
CBFbC/MYH11-D2  for  the  CBFb/MYH11  inv(16)/
t(16;16)  fusion  transcripts.18­ Amplifications­ were­
performed in 25 µl PCR mixture containing 10X Tris 
(pH 8.3; Invitrogen, Brazil), 2.0 mM MgCl2, 0.2 µM 
of each primer, 0.2 mM of each dNTPs, SYBR Green 
(18.75 Units/r × n; Cambrex Bio Science, Rockland, 
ME) and 1 unit of platinum Taq polymerase (Invit-
rogen, Brazil). Cycling conditions consisted of one 
cycle of 95 °C for 3 minutes, followed by 40 cycles 
of 95 °C for 30 seconds, 60 °C for 30 seconds and 
72 °C for 30 seconds. The dsDNA dye SYBR Green 
detection chemistry with melting curve analysis was 
assessed  on  a  RotorGene  3000  (Corbett  Research, 
Australia).­Following­amplification,­melting­curves­
were obtained using a ramping rate of 1 °C/30s from 
72–95 °C­on­the­SYBR­channel.­Post-amplification­
fluorescent­melting­curves­of­amplicons­were­ana-
lyzed using RotorGene software V4.6.94 as shown in 
Figure­2A.­Amplification­of­RUNX1/RUNXT1 t(8;21) 
fusion transcript sequences was performed using a 
nested PCR technique and used to support the mul-
tiplex­real-time­PCR­results.­The­first­amplification­
mixture contained the primers AML1-A and ETO-B 
and the nested PCR used primer sets AML1-C and 
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Figure 1. Conventional karyotyping. partial G-banded karyotype showing translocation (15;17) at diagnosis (marked with arrows).Neto et al
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Figure 2. A) A plot of dF/dT vs. fluorescence shows a characteristic Tm for the control plasmid containing fragments that partially cover PML/RARA 
t(15:17), which are found in 100% of AML M3 patients; RUNX1/RUNXT1 t(8;21), which are found in virtually all cases of AML M2; and the CBFb/MYH11 
inv(16)/t(16;16) translocations, which are found in 88% of cases of AML M4 who have type A transcript. B) PCR amplification of the cDNA breakpoint 
region using primers from the RUNX1 and RUNXT1 genes from samples obtained at 2 different time points. c) Nucleotide and amino acid sequences 
of the RUNX1/RUNXT1 t(8;21) cDNA junction from our patient aligned with the reference sequence (GenBank: dbj_D13979.1). Dots indicate nucleotide 
identity to the reference sequence. Boxed sequences correspond to the region around the breakpoint. The translocation breakpoint in the cDNA is marked 
with an arrow. electropherogram of the patient sequence showing the junction between RUNX1 and RUNXT1.
ETO-D. As depicted in Figure 2B, the outer primers   
of­the­nested­reaction­flanked­a­395­bp­fragment­of­the­
RUNX1/RUNXT1 t(8;21) fusion transcript. In addition 
to conventional qualitative analysis, a real-time quan-
titative PCR (RT qPCR) assay was carried out with 
the same internal primers used for the nested reaction 
(AML1-C and ETO-D)­in­order­to­allow­­ quantification­
of­the­detectable­fusion­gene-specific­products­of­the­
M2  transcript.  The  copy  numbers  were  calculated 
by  comparing  the  standard  curve  generated  using 
serial dilutions of linearized plasmids containing the 
fusion­gene-specific­insert­of­each­transcript­and­nor-
malized to the copy number of the single-copy gene 
ABL­amplified­in­parallel­reactions­(Fig. 3A). Results 
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Figure 3. Amplification plots of RUNX1/RUNXT1 t(8;21)-standard curve (copy numbers ranging from 105 to 100 copies). The x-axis shows the number of 
PCR cycles and the y-axis shows the normalized fluorescence intensity. The threshold cycle values are calculated automatically by determining the point 
at which the fluorescence exceeds a fixed threshold line (indicated by arrows). Amplification plots show results for ABL standard curve (copy numbers 
ranging from 105 to 100 copies) and duplicate reactions on these samples (labeled in white box) are shown A). Amplification plots show results for the 
RUNX1/RUNXT1 t(8;21) duplicate reactions (indicated by hatched circle) from the bone marrow and peripheral blood samples obtained in 2008 and 2010, 
respectively B).early detection of t(8;21) transcript during treatment of a patient with ApL
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were­expressed­as­the­ratio­of­the­fusion-site-specific­
product copy number/ABL copy number × 100%. As 
assessed­by­multiplex­and­quantified­by­RT­qPCR,­
the t(15;17) fusion transcript was detected in .76% 
cells from bone marrow aspirates at the time of the 
initial APL diagnosis.
Adequate precautions were taken to avoid DNA 
contamination using separated locations for extraction 
of­specimen,­amplification­of­DNA,­and­analyses­of­
PCR­products­in­dedicated­laminar­air-flow­cabinets.­
Positive controls (PCR positive for each transcript) 
and negative controls (distilled water) were included 
in each run.
Treatment Outcome
Based­ on­ the­ karyotype­ analysis,­ flow­ cytometric­
  immunophenotyping of bone marrow cells and RT 
qPCR,­our­patient­was­diagnosed­with­APL,­specifically­
FAB APL-M3v. In May 2008, our patient was treated 
immediately with ATRA (45 mg/m² daily)   combined 
with the standard D3A7 (daunorubicin (dauno) + cyto-
sine  arabinoside  (AraC))  induction    chemotherapy, 
which combined dauno (60 mg/m2 × 3 days) with 
cytarabine (200 mg/m² ×­7­days).­The­first­day­of­
later combination therapy was designated as day 0. 
On day +2, the patient gained 5 kg, developed hypoxia 
and crepitant rales in both lungs and febrile neutro-
penia (FN). A chest X-ray showed interstitial diffuse 
alveolar­ ­ infiltrates­ in­ the­ lower­ two-thirds  of  each 
hemithorax  and  pleural  effusion  consistent  with 
either  early  pulmonary  edema  or  acute  lung  injury. 
Blood­cultures­identified­a­Gram­negative­organism­
(Klebsiella    pneumoniae).  The  clinical  picture  was 
considered to be   compatible with a symptom of ATRA 
differentiation  syndrome. As  a  result, ATRA  treat-
ment was halted and the patient was started on dex-
amethasone (10 mg IV twice daily) and imipenem. 
At  the  same  time,  the  patient  received  a  laryngo-
scopic orotracheal intubation, which was continued 
for  two  days  to  maintain  adequate  ventilation  and 
  oxygenation. The patient’s symptoms improved dur-
ing the two days of intubation and ATRA was restarted 
on day +6 without coverage of steroids and was main-
tained until day +42. A repeat bone marrow aspirate 
performed in June (day +27) and August 2008 showed 
that the patient’s leukemia was in complete remission 
and her PB counts were normal. Two more consolida-
tion chemotherapy cycles were administered in June 
and July 2008 (D3A7 in both cycles). Episodes of FN 
were­observed­during­the­first­consolidation­therapy.­
The patient proceeded to planned maintenance ther-
apy in September 08 and commenced with 6-mercap-
topurine (90 mg/m²/day), methotrexate (15 mg/m²/
week) and ATRA (45 mg/m2 daily for 15 days every 
3 calendar months). To date, the patient continues to 
receive maintenance therapy.
To  assess  the  molecular  response  of  treatment, 
RT-qPCR was performed on cells isolated from the 
PB and bone marrow every 3 months after initiation 
of therapy. The results of the consecutive analyses 
are shown in Table 1. During follow up, the patient 
found to be negative for the t(15;17) fusion transcript 
after 3 months of therapy which remained undetect-
able thereafter. However, the emergence of a small 
clone  with  a  t(8;21)  abnormality  was  observed  in 
cells  isolated  from  the  marrow  and  PB  between 
Table 1. Sequential quantification of PML/RARA t(15:17), RUNX1/RUNXT1 t(8;21) in pB and/or bone marrow samples 
at diagnosis and during treatment course.
Date clinical status sample source t(8;21)/ABL t(15;17)/ABL Therapy
30/04/2008 Onset BM1 Negative 76% D3A74 + ATrA
21/08/2008 remission pB2 1.15% Negative 6-Mp5 + MTX6
07/11/2008 remission pB Negative Negative 6-Mp + MTX + ATrA
26/02/2009 remission BM Negative Negative 6-Mp + MTX + ATrA
05/03/2009 remission pB Negative Negative 6-Mp + MTX + ATrA
28/05/2009 remission BM/pB Negative Negative 6-Mp + MTX + ATrA
24/09/2009 remission BM Negative Negative 6-Mp + MTX + ATrA
11/02/2010 remission BM/pB 0.05%3 Negative 6-Mp + MTX
01/04/2010 remission pB Negative Negative 6-Mp + MTX + ATrA
24/05/2010 remission BM Negative Negative 6-Mp + MTX + ATrA
notes:  1Bone marrow;  2peripheral blood;  3The same value in BM and pB;  4daunorubicin (dauno) + cytosine arabinoside (AraC);  56-mercaptopurine; 
6Methotrexate.Neto et al
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3  and  18  months  following  initiation  of  treatment 
(Fig. 3B). Retrospective analysis of the sample col-
lected prior to treatment by a more sensitive nested 
PCR did not show evidence of t(8;21). At that time, 
the patient had no cytogenetic or immunophenotypic 
evidence of M2 disease. Unfortunately, retrospective 
analysis by FISH could not be carried out because 
no more diagnostic bone marrow sample was avail-
able.  The  PCR  amplicon  corresponding  to  t(8;21) 
transcript  that  was  detected  in  August  2008,  was 
sequenced by the dideoxy chain termination method 
using  the ABI  3130  automated  sequencing  system 
(Applied   Biosystems, Foster City, CA). The sequence 
was   compared to known sequences using the BLAST 
Human  Genome  software.  The  sequencing  results 
­ confirmed­that­the­cDNA­showed­a­t(8;21)­variant­
rearrangement (Fig. 2C). Identical DNA sequences 
after  multiplex  PCR  analysis  were  detected  in 
  February 2010 in a small percentage of cells, whereas 
t(15;17) was never detected in the same PB samples. 
At the most recent follow-up, t(8;21) was undetect-
able and the patient was in complete remission.
Discussion
Here, we describe a case of APL-M3v where com-
plete remission was achieved soon after a completion 
of­a­course­of­ATRA­plus­chemotherapy.­Specifically,­
the complete disappearance of the t(15;17) rearrange-
ment was observed, although a novel t(8;21) chro-
mosomal  aberration  emerged.  The  appearance  of 
the t(8;21) fusion gene during the treatment course 
of our patients has not been previously detected. The 
translocation was not detected by PCR at the time of 
APL diagnosis, but was present in PB and bone mar-
row cells obtained from 3 to 18 months after start-
ing  treatment.  It  is  possible  that  the  proportion  of 
M2 leukemic cells at the time of diagnosis was well 
below  the  sensitivity  of  our  nested  PCR  detection 
limit­and­only­became­significant­after­initiation­of­
treatment. This response probably results in a selec-
tion of rare marrow cells with oncogenic fusions by 
chemotherapy.19,20 It is known that chemotherapy has 
a­significant­effect­on­marrow­cell­kinetics­leading­
to their death and forcing many of them to undergo 
  differentiation. However, it cannot be ruled out that 
the chemotherapy induces this translocation.
The abnormal translocation observed in PB cells 
obtained at 3 months was detected after the second cycle 
of  consolidation  therapy  (D3A4)  and    reappeared  at 
15  months  during  maintenance  treatment,  a  period 
without ATRA therapy. Our present study documents 
the disappearance of t(8;21) in bone marrow and PB 
cells collected during scheduled maintenance courses 
when  ATRA  was  combined  with  chemotherapy  in 
November  2008  through  September  2009.  These 
results suggest that ATRA plays a crucial role in restor-
ing the normal function of the myeloid cell transcrip-
tional process, leading to the terminal differentiation 
of leukemic cells. This is consistent with intermittent 
detection of M2 during periods without ATRA ther-
apy. Since ATRA is known to exert growth inhibitory 
effects in non-M3 leukemic cells through apoptosis,21 
it could serve to induce apoptotic changes in M2 leuke-
mic cells. Evidence from in vitro studies demonstrated 
antitumoral effects of ATRA characterized by inhibi-
tion of growth of cell lines derived from malignancies 
other  than APL,  such  as  ovarian  carcinoma,  neuro-
blastoma, and germ cell tumors.22 In non-APL cells, 
ATRA’s role in AML has been observed in the HL-60 
cell line, which lacks PML/RARA­and­is­classified­as­
a variant M2 subtype of AML.23 Moreover, encourag-
ing­results­showing­efficacy­in­non-APL­AML­patients­
have been reported with the use of ATRA alone or in 
conjunction  with  other  agents  such  as  conventional 
chemotherapy13,24–26 or with epi-drugs.27–31
Both the suppression of the M3 leukemic clone 
early in the course of treatment through combined 
therapy and the increase of the M2 clone during con-
solidation therapy argue in favor of 2 independently 
growing aberrant stem cell clones in this patient.
Based on available evidence, additional chromo-
some rearrangements involving t(8;21) and t(15;17) 
are rarely seen in APL patients treated initially with 
ATRA  plus  chemotherapy.32–35  For  example,  two 
independent  anecdotal-based  studies  have  reported 
a coexistence of t(8;21) and t(15;17) chromosomal 
anomalies in their patients at the time of diagnosis, 
and they concluded that t(8;21) may have been the 
first­event­to­originate­from­an­early­leukemic­clone,­
while t(15;17) was acquired later in the course of the 
disease.32,33 In another study,   Movafagh et al36 reported 
a­female­patient­in­which­two­FAB-­ specific­chromo-
some  aberrations  evolved  from  a  single    leukemic 
clone and co-expressed t(15;17) and t(8;21). Recently, 
Qian et al25 described 4 cases of AML treated with 
ATRA alone who were initially   misdiagnosed as APL early detection of t(8;21) transcript during treatment of a patient with ApL
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­ according­to­the­FAB­­ classification.­Three­of­these­
patients achieved CR, but all of them relapsed early. 
Contrary to the case reports outlined above, the case 
described in this report only showed an emergence of 
t(8;21) in the early course of treatment of APL. Close 
monitoring of this patient will permit us to answer 
whether  the  presence  of  the  RUNX1-RUNX1T1 
fusion  transcript  represents  a    reservoir  for  disease 
development  or  a  more  benign,    perhaps  transient 
phenomenon.
conclusion
The multiplex PCR molecular studies played a key 
role in detecting the emerged translocation in fol-
low  up  samples  in  this  patient,  which  would  not 
have been detected using a single PCR assay. This 
finding­supports­the­concept­of­genetic­screening­of­
multiple  translocations  in AML  patients,  not  only 
for monitoring treatment outcome, but also for early 
identification­of­emerging­additional­clones­during­
therapy that may manifest clinically after the course 
of treatment.
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